244 reports of this reaction
2.1% of all LOTEPREDNOL ETABONATE reports
#8 most reported adverse reaction
FATIGUE is the #8 most commonly reported adverse reaction for LOTEPREDNOL ETABONATE, manufactured by Bausch & Lomb Incorporated. There are 244 FDA adverse event reports linking LOTEPREDNOL ETABONATE to FATIGUE. This represents approximately 2.1% of all 11,509 adverse event reports for this drug.
Patients taking LOTEPREDNOL ETABONATE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for LOTEPREDNOL ETABONATE, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for LOTEPREDNOL ETABONATE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 244 FDA reports for LOTEPREDNOL ETABONATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 2.1% of all adverse event reports for LOTEPREDNOL ETABONATE, making it a notable side effect.
If you experience fatigue while taking LOTEPREDNOL ETABONATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.